245 related articles for article (PubMed ID: 22583777)
1. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro.
Yao C; Wu S; Li D; Ding H; Wang Z; Yang Y; Yan S; Gu Z
Mol Oncol; 2012 Aug; 6(4):392-404. PubMed ID: 22583777
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine kinase 1 contributes to doxorubicin resistance and glycolysis in osteosarcoma.
Ren X; Su C
Mol Med Rep; 2020 Sep; 22(3):2183-2190. PubMed ID: 32705189
[TBL] [Abstract][Full Text] [Related]
3. Furowanin A Exhibits Antiproliferative and Pro-Apoptotic Activities by Targeting Sphingosine Kinase 1 in Osteosarcoma.
Wei K; Sun H; Chen X; Chen Q; Li Y; Wu H
Anat Rec (Hoboken); 2019 Nov; 302(11):1941-1949. PubMed ID: 31197942
[TBL] [Abstract][Full Text] [Related]
4. A novel E2F/sphingosine kinase 1 axis regulates anthracycline response in squamous cell carcinoma.
Hazar-Rethinam M; de Long LM; Gannon OM; Topkas E; Boros S; Vargas AC; Dzienis M; Mukhopadhyay P; Simpson F; Endo-Munoz L; Saunders NA
Clin Cancer Res; 2015 Jan; 21(2):417-27. PubMed ID: 25411162
[TBL] [Abstract][Full Text] [Related]
5. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.
Liu L; Zhou XY; Zhang JQ; Wang GG; He J; Chen YY; Huang C; Li L; Li SQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8722-8730. PubMed ID: 30575912
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic value of SC66 in human renal cell carcinoma cells.
Xu M; Wang Y; Zhou LN; Xu LJ; Jin ZC; Yang DR; Chen MB; Zhu J
Cell Death Dis; 2020 May; 11(5):353. PubMed ID: 32393791
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer.
Song L; Xiong H; Li J; Liao W; Wang L; Wu J; Li M
Clin Cancer Res; 2011 Apr; 17(7):1839-49. PubMed ID: 21325072
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.
Li W; Li J; Wang Y; Zhang K; Li N; Tian Z; Ni B; Wang H; Ruan Z
Oncotarget; 2016 Dec; 7(49):80586-80598. PubMed ID: 27811359
[TBL] [Abstract][Full Text] [Related]
9. Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth.
Xue Y; Jiang K; Ou L; Shen M; Yang Y; Lu J; Xu W
Cell Death Dis; 2022 Jul; 13(7):602. PubMed ID: 35831279
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition.
Liao YX; Lv JY; Zhou ZF; Xu TY; Yang D; Gao QM; Fan L; Li GD; Yu HY; Liu KY
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34080667
[TBL] [Abstract][Full Text] [Related]
11. 5,7-Dihydroxy-4'-methoxyisoflavone induces apoptosis by inhibiting the ERK and Akt pathways in human osteosarcoma cells.
Lu X; Zhao J; Li T; Huang M; Liang J; Wei W
Connect Tissue Res; 2015 Feb; 56(1):59-64. PubMed ID: 25363142
[TBL] [Abstract][Full Text] [Related]
12. Liposomal short-chain C6 ceramide induces potent anti-osteosarcoma activity in vitro and in vivo.
Zhai L; Sun N; Han Z; Jin HC; Zhang B
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):274-80. PubMed ID: 26505795
[TBL] [Abstract][Full Text] [Related]
13. Proanthocyanidin B2 inhibits proliferation and induces apoptosis of osteosarcoma cells by suppressing the PI3K/AKT pathway.
Wu X; Yu H; Zhou H; Li Z; Huang H; Xiao F; Xu S; Yang Y
J Cell Mol Med; 2020 Oct; 24(20):11960-11971. PubMed ID: 32914567
[TBL] [Abstract][Full Text] [Related]
14. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
Xu L; Zhang Y; Gao M; Wang G; Fu Y
Biochem Biophys Res Commun; 2016 Apr; 472(4):662-8. PubMed ID: 26920060
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine kinase-1 inhibition sensitizes curcumin-induced growth inhibition and apoptosis in ovarian cancer cells.
Yang YL; Ji C; Cheng L; He L; Lu CC; Wang R; Bi ZG
Cancer Sci; 2012 Aug; 103(8):1538-45. PubMed ID: 22594559
[TBL] [Abstract][Full Text] [Related]
16. Polydatin inhibits proliferation and promotes apoptosis of doxorubicin-resistant osteosarcoma through LncRNA TUG1 mediated suppression of Akt signaling.
Hu T; Fei Z; Su H; Xie R; Chen L
Toxicol Appl Pharmacol; 2019 May; 371():55-62. PubMed ID: 30974157
[TBL] [Abstract][Full Text] [Related]
17. Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells.
Lu PH; Chen MB; Liu YY; Wu MH; Li WT; Wei MX; Liu CY; Qin SK
Oncotarget; 2017 Apr; 8(14):22800-22810. PubMed ID: 28206952
[TBL] [Abstract][Full Text] [Related]
18. Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.
LeBlanc FR; Liu X; Hengst J; Fox T; Calvert V; Petricoin EF; Yun J; Feith DJ; Loughran TP
Cancer Biol Ther; 2015; 16(12):1830-40. PubMed ID: 26252351
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine kinase 1 is a relevant molecular target in gastric cancer.
Fuereder T; Hoeflmayer D; Jaeger-Lansky A; Rasin-Streden D; Strommer S; Fisker N; Hansen BJ; Crevenna R; Wacheck V
Anticancer Drugs; 2011 Mar; 22(3):245-52. PubMed ID: 21360847
[TBL] [Abstract][Full Text] [Related]
20. Targeting sphingosine kinase-1 to inhibit melanoma.
Madhunapantula SV; Hengst J; Gowda R; Fox TE; Yun JK; Robertson GP
Pigment Cell Melanoma Res; 2012 Mar; 25(2):259-74. PubMed ID: 22236408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
